Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

6.550 -0.350 (-5.07%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
30 31 Next >
News headline image
Compass Pathways Plc (CMPS) Q2 2023 Earnings Call Transcript ↗
CMPS earnings call for the period ending June 30, 2023. 
Via The Motley Fool
News headline image
COMPASS Pathways Q2 2023: $148.2M Cash Position, Steady Quarter And 'Strong Progress Across The Business' ↗
Psychedelics biotech COMPASS Pathways’ (NASDAQ: CMPS) consolidated unaudited financial results for the second quarter 2023, ended June 30 are as follows: 
Via Benzinga
News headline image
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More ↗
A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances... 
Via Benzinga
News headline image
July Summary: Largest Psychedelic Compound-Based R&D Stocks Up 16%, On Average ↗
All but 1 of the 6 largest psychedelic compound-based research & development stocks advanced in July and are ranked below as to their performances so far in July: 
Via Talk Markets
News headline image
Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial ↗
UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023: 
Via Benzinga
News headline image
This Unexpected Development Is Yet Another Green Flag for Compass Pathways Stock ↗
For biotechs developing psychedelic therapies, good news comes in many forms. 
Via The Motley Fool
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031
EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Compass' Psilocybin Therapy Proves Helpful In Treating Anorexia: Clinical Trial Shows ↗
UC-San Diego authors assessed psilocybin therapy’s potential as a treatment for anorexia nervosa. They recently shared what are believed to be the first results from such a research study, and the... 
Via Benzinga
AMA Issues Details On First Psychedelics Therapy CPT Code – Thanks To These Psychedelic-Focused Mental Healthcare Companies
By Rachael Green, Benzinga 
Via TheNewswire.com
AMA Issues Details On First Psychedelics Therapy CPT Code – Thanks To These Psychedelic-Focused Mental Healthcare Companies
--News Direct-- 
Via News Direct
News headline image
Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa's Magic Pitch & More ↗
Minneapolis Mayor Deprioritizes Psychedelics: 'We Should Be In The Business Of Helping People' Minneapolis Mayor Jacob Frey recently signed an executive order effectively deprioritizing criminal... 
Via Benzinga
News headline image
AMA Issues Details On First Psychedelics Therapy CPT Code – Thanks To These Psychedelic-Focused Mental Healthcare Companies ↗
The American Medical Association’s (AMA) Panel recently released the full details of a new code for psychological support during the administration of psychedelic treatments. 
Via Benzinga
News headline image
Largest Psychedelic Compound-Based Drug Stocks Up 14% MTD; Now Up 27% YTD ↗
The psychedelic compound-based drug research and development sector is UP 13.6% MTD and is now UP 26.6% YTD and this article analyzes the performance of the 6 largest stocks in the Psychedelic Drug... 
Via Talk Markets
News headline image
Jim Cramer Says It's Time To Buy This Financial Services Stock Down 32% YTD ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Illumina, Inc. (NASDAQ: ILMN) is not even as good as Danaher Corporation (NYSE: DHR). 
Via Benzinga
News headline image
Compatibility Of Psilocybin & SSRIs For Depression, COMPASS Looks At 'Psychedelic-Assisted Therapies' ↗
COMPASS Pathways (NASDAQ: CMPS) shared results from an open-label Phase 2 trial assessing its synthetic psilocybin COMP360 alongside SSRIs for Treatment-Resistant Depression (TRD.) 
Via Benzinga
News headline image
Psychedelic Compound-Based Drug Stocks Up 12% MTD; Now Up 25% YTD ↗
Our Psychedelic Drug Stocks Index is up 12.3% MTD and is now up 25.1% YTD. 
Via Talk Markets
News headline image
Why Lucid Group Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Healthcare Triangle, Inc. (NASDAQ: HCTI) shares climbed 171.2% to $8.84 as the company launched initiative to prevent ransomware attacks in the $35 billion healthcare data market. 
Via Benzinga
News headline image
Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More ↗
First Country Allowing MDMA & Psilocybin For Depression, PTSD Makes Headlines On Saturday, July 1, 2023, Australia became the first country to allow physicians to prescribe MDMA to treat post-traumatic... 
Via Benzinga
News headline image
Top 5 Health Care Stocks That May Collapse This Quarter ↗
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
News headline image
Psychedelic Stocks Jumped 10% Last Week ↗
The FDA released a positive draft guidance for developing psychedelic treatments and the 6 largest stocks in the Psychedelic Drug Stocks Index responded accordingly 
Via Talk Markets
News headline image
Why iMedia Brands Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Prestige Wealth Inc. (NASDAQ: PWM) shares jumped 65.6% to $8.28. Prestige Wealth reported pricing of $5 million initial public offering of 1 million shares of common stock at a price of $5 per... 
Via Benzinga
News headline image
COMPASS Pathways Projects 2027 Commercialization Timeline For Psilocybin Therapy ↗
With timelines for the submission of approval for MDMA-assisted therapy becoming more clear, COMPASS Pathways (NASDAQ: CMPS) has provided their o 
Via Benzinga
News headline image
Alibaba, Kura Sushi USA And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded mixed, with the Dow Jones dropping around 30 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Can Psychedelics Therapy Be Reimbursed? AMA Releases Details On Coding These Procedures ↗
The American Medical Association (AMA) published language concerning the recently-approved Current Procedural Terminology (CPT) III codes applying to psychedelic-assisted therapies, as announced by... 
Via Benzinga
News headline image
COMPASS Pathways Secures Up To $50M In Term Loan Facility With Hercules Capital ↗
Mental health psychedelics biotech company COMPASS Pathways (NASDAQ: CMPS) received funding for its COMP360 Phase 3 program in Treatment-Resist 
Via Benzinga
News headline image
Upward Trend In Largest Psychedelic Compound-Based R&D Stocks Continues ↗
Our Psychedelic Drug Stocks Index, which consists of the 6 largest psychedelic compound-based research & development companies, was up 3.4% this week, up 7.1% in June, up 6.3% in May, and is now up... 
Via Talk Markets
News headline image
Can Compass Pathways' Stock Gain 458% Like Wall Street Is Expecting? ↗
Wall Street might have the timing wrong, but their hopes aren't misplaced. 
Via The Motley Fool
News headline image
The 3 Best Psychedelic Stocks to Buy Now ↗
Psychedelic stocks promise to bring therapeutics to market that were taboo until recently and have huge upside. 
Via InvestorPlace
News headline image
Upward Trend In Major Psychedelic Compound-Based Research & Development Stocks Continue ↗
There are 6 constituents in our munKNEE Psychedelic Drug Stocks Index and 5 of them advanced this week and are now all up MTD. 
Via Talk Markets
News headline image
Major Psychedelic Compound-Based Research & Development Stocks: June Update ↗
Psychedelic Drug Stocks Index has been revamped with the removal of Cybin (CYBN) which has dropped below $100M in market capitalization leaving 6 constituents in the Index 
Via Talk Markets
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.